Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

4.85
+0.06001.25%
Post-market: 4.950.1000+2.06%19:58 EDT
Volume:1.81M
Turnover:8.71M
Market Cap:373.52M
PE:-3.62
High:4.94
Open:4.88
Low:4.71
Close:4.79
Loading ...

Altimmune initiated with a Buy at Stifel

TIPRANKS
·
08 Jan

BUZZ-Viking set to double in 'challenging' year for obesity drug developers

Reuters
·
01 Jan

Low Market Cap Cryptos Offering High-Risk, High-Reward Opportunities!

CoinMarketCap
·
29 Dec 2024

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

GlobeNewswire
·
26 Dec 2024

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

GlobeNewswire
·
23 Dec 2024

B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)

TIPRANKS
·
21 Dec 2024

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…

Zacks Small Cap Research
·
20 Dec 2024

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion

Reuters
·
20 Dec 2024

Shares of Viking Therapeutics up 4.2%, Amgen up 1%

THOMSON REUTERS
·
20 Dec 2024

Weight Loss Drug Developers Rise After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected

THOMSON REUTERS
·
20 Dec 2024

BUZZ-Weight-loss drug developers gain after Novo's obesity drug underperforms in study

Reuters
·
20 Dec 2024

Weight Loss Drug Developers Rise Premarket After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected

THOMSON REUTERS
·
20 Dec 2024

Shares of Viking Therapeutics up 9.3%, Structure Therapeutics up 3.4%, Altimmune up 1.7% Premarket

THOMSON REUTERS
·
20 Dec 2024

Altimmune to Join Nasdaq Biotechnology Index

MT Newswires Live
·
19 Dec 2024

BUZZ-Altimmune up on addition to Nasdaq Biotech index

Reuters
·
19 Dec 2024

Altimmune to be added to the Nasdaq Biotechnology Index

TIPRANKS
·
19 Dec 2024

Altimmune Added to Nasdaq Biotechnology Index

THOMSON REUTERS
·
19 Dec 2024

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

GlobeNewswire
·
19 Dec 2024

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

PR Newswire
·
18 Dec 2024

ALT Resources PLC Sets Date for Annual General Meeting

TIPRANKS
·
18 Dec 2024